Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

109.61 -1.87 (-1.68%)
Official Closing Price Updated: 7:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals
Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction. 
Via Benzinga
Exposures Product Safety
The Top 3 Vanguard ETFs of 2025 (so Far) Share This 1 Striking Common Denominator
Via The Motley Fool
Topics Bonds ETFs
Exposures Debt Markets
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) Technical Analysis observations.
Exploring NOVARTIS AG-SPONSORED ADR's Technical Signals and Breakout Potential: Promising Signs: NOVARTIS AG-SPONSORED ADR Setting the Stage for a Breakout. 
Via Chartmill
No Fear And No Panic After A 10% Correction = No Bottom
In this video lesson, I discuss the overall market, my books, and my game plan moving forward after Friday's ugly sell-off. 
Via Talk Markets
Topics Stocks / Equities
Is the Market Bullish or Bearish on Novartis?
Via Benzinga
FDA OKs Novartis Prostate Cancer Treatment, Triples Eligible Patient Pool
FDA approves Novartis' Pluvicto for advanced prostate cancer patients who have received ARPI therapy. 
Via Benzinga
Exposures Product Safety
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) is an undervalued gem with solid fundamentals.
NOVARTIS AG-SPONSORED ADR has caught the attention as a great value stock. NYSE:NVS excels in profitability, solvency, and liquidity, all while being very reasonably priced. 
Via Chartmill
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness. 
Via Benzinga
FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease
Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory reviews continue. 
Via Benzinga
Exposures Product Safety
Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders
Monte Rosa's MRT-6160 shows promising Phase 1 results, with Novartis backing its development in a deal that could reach $2.1B in milestone payments. 
Via Benzinga
Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy
Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a treatment option. 
Via Benzinga
The Best Vanguard ETF to Invest $1,000 in Right Now
Via The Motley Fool
Topics ETFs
These 2 Vanguard ETFs Are Crushing the S&P 500 in 2025. Should You Buy?
Via The Motley Fool
Topics ETFs Stocks
Exposures US Equities
Teladoc Health Partners With Eli Liily's LillyDirect to Expand Access to Zepbound For Weight Loss
Teladoc Health teams up with Eli Lilly's LillyDirect to improve Zepbound access, offering direct home delivery and comprehensive obesity care support. 
Via Benzinga
Novartis Earns Near-Best Overall Rating As Profit Growth Climbs
Novartis ranks No. 1 among in the 33-stock Medical-Ethical Drugs industry group. Novartis got a Composite Rating upgrade to 96 on Wednesday. 
Via Investor's Business Daily
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) stands out as a stock that provides good value for the fundamentals it showcases.
Uncover the potential of NOVARTIS AG-SPONSORED ADR, an undervalued stock. NYSE:NVS maintains a strong financial position and offers an appealing valuation. 
Via Chartmill
Novartis Earnings Surprised The Street; Still Going Strong Despite Market Correction
Highly ranked Novartis is forming the right side of a long cup base with a buy point of 120.92. And it's literally running higher. 
Via Investor's Business Daily
Roche Touts Food Allergy Drug As Superior Than Oral Immunotherapy
Roche's Xolair outperformed oral immunotherapy in a Phase 3 trial for food allergies, showing better tolerance and fewer adverse events. 
Via Benzinga
3 Dividend Stocks That Are No-Brainer Buys Right Now
Via The Motley Fool
Court Dismisses Novartis Challenge To Medicare Drug Price Negotiation Program
A federal court rejected Novartis' legal challenge to the Medicare Drug Price Negotiation Program, ruling that it does not impose unconstitutional fines, takings, or compelled speech. 
Via Benzinga
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
Multiple sclerosis patients report severe side effects, including relapses and mobility issues, after switching from Tysabri to Tyruko in an NHS cost-saving move. Regulators and experts are assessing... 
Via Benzinga
This Kraft Heinz Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
Via Benzinga
Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal
Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late-stage anticoagulant, to its cardiovascular portfolio. 
Via Benzinga
Super Bowl Commercials 2025: Complete List of Super Bowl LIX Ads And Companies Behind Them
The list of Super Bowl LIX commercials and the companies behind the Super Bowl ads. 
Via Benzinga
Super Bowl LIX Commercials: AI, Celebs, Muppets, Warren Buffett-Linked Brand Take The Spotlight
A list of Super Bowl LIX commercials and the celebrities and athletes attached to star in the ads. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond
Via The Motley Fool
Novartis Ag (NVS) Q4 2024 Earnings Call Transcript
NVS earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Novartis Gets Retail Chatting After Upbeat Q4, But Sentiment Stays Tepid Amid Volatile Trading
The company is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year. 
Via Stocktwits
Topics Intellectual Property
Exposures Intellectual Property
Novartis Edges Higher On Sales Beat As Competition Looms For Its Biggest Moneymaker
The company's biggest moneymaker is expected to face off with lower-cost generics this summer. 
Via Investor's Business Daily
Topics Earnings
Exposures Financial
US Stock Futures Climb After Apple Beats Q4 Expectations: Expert Says Tech Stocks Hold Above Key Level Despite DeepSeek Impact
US stock futures climbed on Friday, pointing to a third straight week of gains fueled by strong corporate earnings. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.